Coherus Biosciences (CHRS) Stock News
$CHRS · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Coherus Biosciences (CHRS) in the past 30 days. Coherus Biosciences’ next earnings report is scheduled for Thursday, Nov 5.
The wire on $CHRS
newest first · updated · direct subject stories onlyCoherus Oncology retains Oppenheimer to market legacy biosimilar assets
Coherus Oncology (CHRS) hired Oppenheimer & Co. to sell its legacy biosimilar assets. Shareholders of record on Sept 30 will receive CVRs that pay out a pro rata share of net proceeds from the sale. Distribution is Oct 7.
bullish 65 · impact 30The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card Coherus Biosciences (CHRS) stock: common questions
What is the latest Coherus Biosciences stock news?
The highest-impact CHRS story BORSA published in the past 30 days:
· Coherus Oncology retains Oppenheimer to market legacy biosimilar assetsWhen does Coherus Biosciences report earnings?
Coherus Biosciences’ next earnings report is scheduled for Thursday, Nov 5.